Brian Sweis, MD, PhD: A Physician-Scientist’s Approach to Psychiatry

Brian Sweis, MD, PhD, logging his clinical rounds notes while keeping an eye on the mice in his latest experiment.

The past few decades have seen a surge in neuroscience breakthroughs, but translating those findings into better outcomes for patients has been slow and, in some cases, non-existent. Neuroscientists who train as clinicians can narrow that interdisciplinary divide.

Brian Sweis, MD, PhD, a second-year psychiatry resident and post-doctoral researcher at The Mount Sinai Hospital, is learning that discoveries in the lab can help inform how psychiatrists conceptualize the biology underlying complex emotions. In his most recent experiments, he investigated where in the brain emotions like regret stem from, and how this could go awry in mood disorders.

“We learned that there may be two distinct types of regret in the brain: one linked to depression, and another linked to resilience, which differ based on how people view their own mistakes and what could have been done differently,” he said. “I realized that we may even be able to access the root of some of these seemingly similar but fundamentally distinct thought processes if we structure psychiatric interviews with patients more precisely. This could help us identify which type of regret a patient is experiencing—either an emotion that is healthy and adaptive (and should be reinforced) versus one that may be pathological (and targeted for treatment).”

Dr. Sweis anticipates that as he continues to grow as a budding psychiatrist, the connections between his research and clinical experience will help him better bridge the worlds of science and medicine.

An indirect path to psychiatry
Dr. Sweis was first introduced to neuroscience as an undergraduate at Loyola University in Chicago, where he worked in a research lab studying how stress can affect the body and brain in rodents. At the same time, he was drawn to a psychology professor who was studying similar concepts in humans. He realized that neuroscience lay at the intersection of the two. “I fell in love with neuroscience when I learned that something as intangible and abstract as a psychological concept could have concrete biological underpinnings,” he said.

He decided to double major in psychology and biology, and minored in neuroscience and philosophy. “I was a total nerd about everything neuroscience,” he said. “I remember thinking at one point that I definitely didn’t want to go to medical school. Instead, I wanted to be a professor, run a research lab, train my own students, and be a full-time scientist.”

He was most interested in areas of science where multiple fields overlapped. “That’s where the most exciting innovation happens,” he said. Towards the end of college, he learned he could pursue his research passions while in medical school and work at the intersection of two often separated career paths as a physician-scientist.

Dr. Sweis enrolled in the dual degree MD-PhD program at the University of Minnesota Medical School (UMN), which splits the four years of medical school and adds a four-year PhD program in the middle. For his PhD in neuroscience, he explored the complex cognitive processes around how the brain makes decisions. “I was fascinated by how we could take abstract concepts like thought, memories, and imagination, and boil them down to the physical properties of a brain cell that you can touch and directly measure,” he said.

Most of the breakthroughs in basic neurobiology occur in animal studies because the technologies available in that space are more advanced, but this is often far removed from affecting patient care. However, Dr. Sweis set out to work across species with rodent and human subjects in parallel in order to accelerate the “bench to bedside” process of translational research.

At UMN, Dr. Sweis was part of the first group of researchers to discover that humans are not the only species that are capable of experiencing regret. Combining elements from decision neuroscience with behavioral economics, he found that even rodents are sensitive to the mistakes they’ve made when realizing that alternative actions could have led to better outcomes. He also found that avoiding future regret can be a strong motivator for learning—mice will even sacrifice food to do so.

Related to this work, Dr. Sweis was first author on a Science paper showing that rodents also tend to overvalue rewards they’ve already invested in, even when it’s clear they should cut their losses. This well-studied cognitive bias is known as the sunk cost fallacy, and it was thought to be a psychological phenomenon unique to humans. Importantly, Dr. Sweis helped craft a way to study these concepts so that they could translate to animal models of psychiatric disorders. His work in comparative biology and evolutionary neuroeconomics landed him on the 2020 Forbes 30 Under 30: Science list. He has also received best PhD awards through UMN, nationally through the Council of Graduate Studies, and internationally through the Society for Neuroscience.

As a clinician, Dr. Sweis originally planned to train in neurology. But over the course of his PhD, he learned that the applications of what he was studying aligned more with the depth of training he could gain from a residency program in psychiatry.

“I realized psychiatry was more in line with the questions I found to be the most fascinating, and tied back to my philosophy interests in undergrad,” he said. “How does the mind work? Where does motivation come from? What happens when the machinery in our brain that controls the way we make decisions starts to physically break down? Whether it’s the result of a neurological insult like a stroke or psychiatric event like trauma, I wanted to know more about the biology that causes us to behave and think the way we do. To fully unpack all of the ways a clinician can deconstruct the origins of behavior, I knew I needed to be formally trained as a psychiatrist.”

Mount Sinai’s physician-scientist residency track
Dr. Sweis chose The Mount Sinai Hospital because “the institution as a whole values research at every level, not just a certain department or an individual or two,” he said. “Mount Sinai was built around accelerating and providing robust training experiences and research opportunities, and that’s one of its biggest strengths toward innovating new treatments for patients.”

The Mount Sinai Hospital was also a good fit because the training directors, Antonia New, MD, Asher Simon, MD, and Mercedes Perez-Rodriguez, MD, PhD, wanted to accelerate his research momentum concurrent with his clinical training as a physician.

“They readily identified that my talents lie with being a scientist,” he said. “They told me they would do everything they could to powerfully launch my career as a physician-scientist because that’s where I would thrive the most.”

To that end, during his first year of residency, he split his time as an intern seeing patients (including in the ICU and ER during the height of COVID-19), and the other half initiating experiments on how regret-related processes in the brain are altered in depression.

“I began working on this experiment the first day I moved to New York,” he said. “My training directors saw the clear path forward, entrusted my vision and drive, and supported me in every way. We’re working to publish these discoveries right now.” Within the first six months of residency, Dr. Sweis was awarded third place for best research by a psychiatry resident in New York City by the American Psychiatric Association.

Finally, Dr. Sweis chose The Mount Sinai Hospital because of the faculty he wanted to work with, including Eric Nestler, MD, PhD, Scott Russo, PhD, and Denise Cai, PhD. Dr. Sweis launched his first set of experiments in Dr. Nestler’s and Dr. Russo’s labs studying how regret may be processed differently in rodents that develop depressive-like symptoms following exposure to stress (stress-susceptible individuals) versus animals that are more stress-resilient.

“Dr. Nestler and his colleagues provided a home for me to continue my research from UMN in an independent manner,” he said. “The opportunity for collaboration was obvious: I took a well-validated model of depression their labs and others developed, and combined it with my expertise in neuroeconomics, which was quite new to their labs.”

Now that he completed his first set of experiments and has hit the ground running, Dr. Sweis is expanding his research horizon and learning from other expert faculty including Dr. Cai, a leader in the field of memory research. Dr. Cai’s lab leverages cutting-edge technology that she and others developed to image the living brain in ways never before possible in order to ask deeper questions about how experiences are dynamically processed and stored.

The microscope and raw footage of a rodent’s brain. Image credit: Daniel Aharoni, PhD, and Denise Cai, PhD.

Her group developed a miniature microscope the size of a penny that can be implanted into a rodent’s brain. The microscope can record videos of individual neurons that together look like stars in the night sky, where each flickering light represents a biological event. This electrical cellular activity is engineered to be converted into a visual signal that can be captured with a camera. Hidden in this display are coordinated “constellation-like” patterns that together represent aspects of a memory distributed across a network of neurons.

“This type of work is truly incredible,” said Dr. Sweis. “Information represented this way in the brain—in networks—would have previously otherwise gone unseen without this technology. Identifying new ways in which these complex processes break down is only the beginning toward developing a richer understanding of psychiatric illnesses.” Dr. Sweis and Dr. Cai together recently published a review article on the current state of this research and where these new technologies are taking the field.

Career plans
A fundamental issue in brain research is that animal work and human work can be very disconnected, but Dr. Sweis plans to keep a foot in both worlds. He sees his translational research ultimately extending back into clinical patient populations, where he has aligned interests with another mentor: Helen Mayberg, MD, director of the Nash Family Center for Advanced Circuit Therapeutics. As a neurologist who works in neurosurgery to advance next-generation treatments for psychiatric disorders through deep brain stimulation, she emulates the type of neuroengineering approach to psychiatry Dr. Sweis is aiming to grow further into with his research and clinical background. While certain techniques and questions can only be investigated in mice, he hopes some of the insights he gains by studying animal behavior in complex ways can bring a different spin or new elements to questions being asked on the human side (such as Dr. Mayberg’s research).

For example, deep brain stimulation doesn’t work for every depressed patient. “Why is that? Is the implanted device slightly missing the intended target? Or does this person have a fundamentally distinct sub-type of depression in which treatments would be better tailored toward a different pathway in the brain?” said Dr. Sweis. “One of the primary goals of my translational research is to be able to differentiate sub-types of a psychiatric disease by refining the way in which we understand how behaviors come about in the first place—and to be better at describing those processes.”

Scientists trained as physicians, like Dr. Sweis, are in a unique position to understand and enhance the links between preclinical research and clinical applications in humans to advance patient treatments. “During my residency interview, my program directors told me that the toolkit of a psychiatrist lies in the interview,” he said. “It’s a surgical interview—much like a scalpel is to a surgeon, so is the art of interviewing a patient to a psychiatrist.”

He hopes that his research in neuroeconomics will equip psychiatrists with a new language to dissect the multifaceted drivers of behavior and sharpen the precision of a surgical interview such that it can tap into the different circuits at play. This is one of the goals of the emerging field of computational psychiatry, and he knows his training as a clinician is making all the difference as he moves toward that goal.

“By learning how to practice psychiatry and working directly with patients, I can begin to identify what needs to change the most in this field and where to best direct my efforts as a neuroscientist,” he said.

Mount Sinai’s Department of Psychiatry is one of the largest and most prolific in the world. With our new series, Inside Mount Sinai Psychiatry, we showcase stories from every corner of our Department including our training programs, patient care teams, and scientists. We believe psychiatry and mental health are the building blocks to fulfilling lives and thriving societies; via these stories about our faculty, trainees, and staff, this series shows the myriad ways we work toward that. Whether it’s manning the front desk of an opioid treatment clinic, researching how psychedelics work in the brain, or training future clinician-scientists, our team is relentlessly pursuing the best for those suffering from mental health issues.

Should I Tell My Doctor About My Cannabis Use?

Cannabis joint in the hand

Now that New York and many other states around the country have decriminalized medicinal and recreational cannabis, some are interested in partaking. To those people, Yasmin Hurd, PhD, Director of the Addiction Institute of Mount Sinai, advises that marijuana is just like any other drug, even if it’s now legal.

Dr. Hurd is an internationally renowned expert on addiction and related psychiatric disorders who has been at the forefront of research into cannabinoid (CBD), a substance derived from the hemp plant that is now seen in many retail stores. In this Q & A, she explains what you need to know if you are heading to the cannabis dispensary and why disclosing marijuana use to your primary care physician is critical.

What advice do you have for those new to marijuana who are interested in partaking now that recreational use is legal?

You have to really be careful about where you obtain your cannabis. There are bad actors out there, and we have seen that some items which have been marketed as cannabis can actually contain products that are not. Recently, we have seen cannabis that has been laced with fentanyl, which is a highly potent and highly addictive opioid. So, the source from which you obtain your cannabis is critical. For now, the safest way to get marijuana in New York is to get a prescription from a physician and buy it in a state dispensary.

Should I tell my doctor that I am using marijuana? Why?

It is critical to tell your doctor if you are using any cannabis product. Like any drug, cannabis is broken down into various active chemicals that your body can use by liver enzymes. If you are taking any other pharmaceutical drugs, cannabis may interact with the same liver enzymes and either diminish or increase the activity beyond its intended use. So, your doctor absolutely has to know to avoid a potentially dangerous drug interaction.

One of the benefits of legalization is that there should not be any risk in being honest with your doctor about your cannabis use. The more honest that you can be, the better medical care you can receive.

Is it true that marijuana is non-addictive?

Many people don’t realize that you can become addicted to cannabis. In fact, the rate of diagnosis of “cannabis use disorder” is about 30 percent in people who frequently use the drug. That percentage is not much different from highly addictive drugs like cocaine and opioids even though cannabis is not as highly addictive.

The reason that we have such a high prevalence of cannabis use disorder being diagnosed is that a greater number of people use cannabis, so more people can convert into addiction. Often, the higher addiction is due to the higher potency of today’s cannabis.

What specifically is different about today’s marijuana?

Today’s recreational cannabis has a very high concentration of THC (short for delta-9-tetrahydrocannabinol), which is the main psychoactive ingredient in cannabis. It has gone from approximately four percent THC to, in some products, nearly 24 percent. And certain products, even those obtained from dispensaries, could have 70 percent THC. This is much higher than 10 or 20 years ago.

The greater the THC concentration, the greater the potential impact on a user’s mental health, and the greater the potential to become addicted. For a safer, higher-quality product, look for cannabis that has a verified certificate of analysis—this indicates that the product has been thoroughly checked for contaminants, pesticides, and other harmful materials, and it allows you to view its THC levels as well as other ingredients.

Is hemp-based THC safer than cannabis-based THC?

In short, no. THC is the same if purified in a safe manner for human use, whether it is derived from hemp or cannabis. However, the amount of THC that can be produced from hemp is low—the plant contains less than .3 percent THC—, so most THC is obtained from cannabis.

It is important to understand that even though marijuana may be legal for recreational and medicinal purposes in New York, on the federal level it is still a Schedule 1 drug which means that it is considered to have no accepted medical use and a high potential for abuse.

However, CBD—which is derived from hemp—is federally legal. There are some who try to get around cannabis’ federal status by selling a hemp-based THC product under the name ‘delta-8-THC.’ In the cannabis plant, it is delta-9-THC that causes the ‘high’ and, large concentrations of the substance can cause mental health issues. While there is not a lot known about delta-8-THC, we do know that it can cause euphoria, though milder than delta-9-THC.

Many companies are marketing delta-8-THC as the safer—and legal—option, but that is not true. For example, since the amount of THC in the hemp plant is low, some manufacturers try to forego the natural process of deriving the substance and use chemicals to artificially increase the amount of delta-8-THC. Additionally, some bad actor companies are faking their certificate of analysis to say that their product is delta-8-THC, when it turns out that it contains delta-9-THC and harmful materials like lead and heavy metals.

Are there any other drawbacks to frequent cannabis use?

In addition to potentially developing an addiction to cannabis, with use of highly potent cannabis products, we see mental health related problems. For example, issues with attention, memory, and cognition. Those are a side effect of chronic cannabis use, and even occasional use can impair motor issues. We also see the risk for psychosis, especially in certain younger people, when they use cannabis.

And, for any drug that is being consumed by smoking, you also incur the risk of pulmonary issues as smoking which is not good for your lungs.

Has marijuana been proven to alleviate any medical conditions?

There are certain synthetic THC products that have been approved by the U.S. Food and Drug Administration (FDA) for anti-nausea purposes to help increase the appetite of people going through chemotherapy. The FDA has also approved the use of CBD, in particular Epidiolex®, for two rare childhood forms of epilepsy.

Other than that, neither cannabis nor CBD have been approved for anything else. But there are a lot of clinical trials currently being done. So we’ll see how those pan out in a few years.

How does legalizing marijuana benefit the medical community?

Legalizing marijuana is a double-edged sword for the medical community. We want to make sure that people are healthy, and any time you take a drug that you most likely do not need that can have negative effects on mental health, that’s not great. But the legalization of marijuana makes it easier for patients to be honest with their doctors about their cannabis use, which overall gives patients better outcomes because a physician will know exactly what their patient is taking and can, therefore, guide their care in a much better way.

Also, for my fellow researchers, the fact that cannabis is no longer illegal in some states makes it easier for us to investigate what may be the benefits and adverse effects of its use for certain disorders. It also allows us to better guide physicians and their patients about how to use cannabis, if they choose to use cannabis.

Yasmin Hurd, PhD, is the Ward-Coleman Chair of Translational Neuroscience and the Director of the Addiction Institute at Mount Sinai. She is currently the principal investigator on a clinical trial of CBD for treating opioid use disorder, a neuroimaging study of CBD’s effects on the human brain, and a study looking at neurodevelopmental effects of cannabis and its epigenetic regulation.

Pandemic’s Toll on Mount Sinai Front-Line Staff Is Surveyed, and Addressed

Recharge rooms were created across the Health System in one of many initiatives informed by surveys of front-line staff.

Front-line staff who were already feeling burnout showed the most signs of mental distress during the height of the COVID-19 pandemic, while those who fared best had an active social network and felt supported by their supervisors. These were among the many lessons learned by a team of Mount Sinai researchers based on two surveys of front-line Mount Sinai staff in 2020.

“The main takeaway is what most people would expect—that if you’re involved in health care during a pandemic, it’s going to take its toll,” says Jonathan Ripp, MD, MPH, Dean for Well-Being and Resilience and Chief Wellness Officer at the Icahn School of Medicine at Mount Sinai. “But beyond that, we were able to identify what types of things may put you at greater or lesser risk of these mental health outcomes, and inform how we can try to mitigate them.”

The results were used in real time to develop programs to help Mount Sinai staff handle the pressures of the pandemic, Dr. Ripp says, and they are being shared with other institutions through journal publications and a Well-Being Toolkit developed by the Office of Well-Being and Resilience.

The three mental health outcomes studied were depression, anxiety, and post-traumatic stress disorder related to the COVID-19 pandemic. Among the more than 3,000 front-line staff members who responded to an initial survey in April and May 2020, 39 percent screened positive for at least one of these outcomes. The most significant factor predicting mental health symptoms was the presence of pre-pandemic burnout, according to studies published by the Mount Sinai team in The Journal of Clinical Psychiatry and Chronic Stress.

At the start of the pandemic, Mount Sinai focused on meeting the basic needs of front-line staff, such as providing free or subsidized food onsite.

“This means that if you already felt exhausted, fatigued, and detached from your work, you were more likely to develop these mental health symptoms during the pandemic,” says investigator Lauren Peccoralo, MD, MPH, Senior Associate Dean for Faculty Well-Being and Development, and Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. The research team emphasized that burnout is distinct from other mental health issues in that it is more a function of the work environment, and can be remedied by strategies that support workers.

In the earliest days of the COVID-19 pandemic, the Office of Well-Being and Resilience assembled a group of researchers with backgrounds in psychology, psychiatry, survey design, and statistical analysis to examine its mental health consequences on the workforce, in an effort initiated by Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System.

The group sent surveys to more than 6,000 physicians, nurses, social workers, chaplains, and other front-line staff at The Mount Sinai Hospital during the height of the pandemic’s first wave in April and May 2020 and again seven months later. In the first survey, more than 3,000 respondents answered questions from three diagnostic series: the General Anxiety Disorder 7, the Personal Health Questionnaire 8, and the Post Traumatic Stress Disorder checklist. In the self-screening for depression, for example, about 26 percent of respondents reported that on more than half the days of the week, they felt such symptoms as taking little interest or pleasure in doing things, feeling hopeless, losing their appetite, having trouble staying or falling asleep, or difficulty concentrating.

The survey also asked open-ended questions about the respondents’ concerns. “There were a lot of infection-related worries. People were worried about PPE, about infecting colleagues or bringing COVID-19 home to their family members,” says Jordyn Feingold, MD, an investigator in the study, who graduated from Icahn Mount Sinai in May 2020 and is now a psychiatry resident. “There were worries about basic needs like getting food at work, and existential worries like ‘When is this going to end?’ and ‘When is life going to return back to normal?’”

The aid facilitated by the research team fell into three categories: providing basic needs like food and the proper personal protective equipment (PPE) and other materials; providing up-to-date information through channels including web sites and system-wide email broadcasts; and creating well-being spaces and onsite mental health and peer support to reduce the stress experienced by health care workers.

A Second Survey Finds an Increase in Burnout

The surveys also asked questions related to resilience, Dr. Ripp says. Specific factors that were found to be protective against mental health symptoms included getting enough sleep and exercise, having social emotional support, not using substances to cope, having sufficient PPE, and feeling supported by hospital leadership and valued by supervisors.

Simply feeling heard was also important, Dr. Feingold says. “Whether or not we have it in our control to fix all of these things right away,” she says, “just validating the concerns and letting people know that they’re not experiencing this in isolation, I think was really powerful.”

In the second survey, conducted from November 2020 to January 2021, more than 1,600 responded and of those, 786 staff provided follow-up responses on their mental health and well-being. The results indicate that mental health symptoms have declined, but the prevalence of burnout has increased, Dr. Peccoralo says. “We are still analyzing the data, but one thought is that the traumatic situation has largely gone away, but the work hasn’t. We’re all still working really hard, maybe even harder than we have ever worked before,” she says. “So we have to think about how we can tell if we are pushing people too much, and what we can do about it.”

The surveys have served an important role in helping Mount Sinai take care of its own, and in advancing knowledge of the mental health consequences of responding to a pandemic, Dr. Ripp says.

The needs identified in the surveys have informed the development of new initiatives, including the launch of the Center for Stress, Resilience, and Personal Growth, says its Clinical and Research Director, Jonathan DePierro, PhD, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. The Center is an innovative service supporting the resilience and psychological health of all Mount Sinai faculty, staff, and trainees through a series of evidence-based resilience workshops, a resilience-promoting app available for download on Sinai Central, ongoing outreach efforts, and up to 14 treatment sessions in its confidential faculty practice.

“Let’s hope that it’s a very long time before something like this pandemic happens again, but should it happen, I think the lessons that we’ve learned can apply,” Dr. Ripp says. “And then of course we can share those lessons, so that other institutions that haven’t had the opportunity to study this trajectory can learn from our experience.”

Alexa Salguero-Diaz: From Trauma and Truancy to Valedictorian

Alexa on graduation day with her therapist, Monica Rojas, PsyD.

 

On June 25, Alexa Salguero-Diaz joined her classmates from her laptop to deliver her valedictorian speech for their virtual high school graduation. “A few years ago, I didn’t think about my future,” she said. “I didn’t even think I had one. But now, I’m actually excited for my future, and the adventures I’m going to have.”

It had been a long and painful journey for her to get to this point.

Alexa didn’t have an ordinary childhood, and she didn’t graduate from an ordinary high school. She graduated from Mount Sinai’s Comprehensive Adolescent Rehabilitation and Education Service (CARES), an integrated program for teens who struggle with mental health and/or substance use that combines a high school education with intensive psychological treatment. Founded in 1990, CARES aims to prevent the effects of mental illness and substance use on adolescents’ brain development, the subsequent decreased academic performance, and the ripple effects on their lives. CARES is the only program of its kind in the country.

When Alexa transferred to CARES, she was 17 and had been hospitalized for the 13th time for self-harm with the intent to commit suicide. The trauma she experienced due to abuse by a family member at a young age resulted in a lifetime of depression, multiple forms of self-harm, anxiety, anorexia, and bulimia, and addiction to multiple substances including Xanax.

After two years at CARES working with her therapist, Monica Rojas, PsyD, and in various targeted therapy groups including dialectical behavioral therapy (DBT), substance abuse, and milieu therapy, Alexa is in a much better place. She hasn’t used substances for three years, and is stable with no self-harm or suicidality. She is also armed with coping mechanisms and resources to get through any lapses that may arise.

“If I feel like I want to hurt myself, I let Monica or someone else know,” she said. “I’m not scared to go back to the hospital if I need to.”

Childhood challenges

Many of Alexa’s mental health problems can be traced back to genetic vulnerabilities, given her family history of depression and trauma, and the fact that she was abused at the age of seven. She never told anyone, and believes she denied and avoided the memories because it didn’t feel safe to talk about them.

In middle school, bullying and sexual harassment became a huge issue, which led to coping through substances and other risky, life-threatening behaviors. Alexa slowly began to realize there were connections between her past and present as she worked with therapists to understand how she was trying to master the traumas by re-enacting them over and over. “That’s when the sadness started coming. I started hurting myself, and I wanted to die every day.”

As a first generation Salvadorian-American, Alexa made brave efforts to share these stressors with family. But given how taboo it is to speak of abuse in so many cultures, she was unable to receive the support and validation needed.

The trauma from her abuse haunted her, and drugs helped her forget—temporarily. “I got addicted to Xanax, molly—whatever was around, but especially Xanax. I skipped school just to do drugs.” Alexa put herself in dangerous situations in order to use substances, which further exacerbated her trauma.

“I wanted to take away all my bad thoughts and go to another world, but in reality, it made things worse. I just wanted to die,” she said.

The abuse also created a sense of worthlessness and disgust. “It all started because of that sexual trauma when I was younger. I just felt so useless and ashamed of myself and disgusted with how I am, how I look.” This led to anorexia and bulimia in her sophomore year, coupled with substance abuse and suicidality.

“When I was in my original high school in the Bronx, that’s where my depression and anxiety got really bad,” she said. “I was actually hospitalized 12 times when I was there.” Alexa’s education was frequently interrupted due to these hospitalizations with an average stay of one month. Additionally, one serious attempt landed her in a coma for a week and subsequently hospitalized for two months. Because of these multiple prolonged hospitalizations, Alexa fell behind in school. At age 17, she was still in need of 22 credits and all five of her Regents exams in order to earn her high school diploma.

The path to recovery

In 2019, Alexa transferred to CARES, on the recommendation of psychiatric hospital staff. “It was really the best choice I made,” she said. “I felt so much support.”

Dr. Rojas believes falling behind in school fed into Alexa’s shame and mental health issues, and that interventions for her mental health needed to be integrated with keeping her education on track.

“CARES is the kind of place where we say ‘You can do this,’ and we will work together as a team to help you reach your academic and mental health goals,” she said. Her steady progress in therapy fostered autonomy and confidence, which influenced her academic achievements.

CARES functions as a “warm handoff,” bridging the gap between inpatient and outpatient therapy. The program’s multidisciplinary team onsite consists of psychologists, psychiatrists, social workers, a psychiatric nurse practitioner, DOE teachers, and guidance counselors, along with trainees in these disciplines.

The CARES treatment team works together to make an individualized treatment plan for each patient that includes individual therapy two times per week, group therapy five times per week, family therapy, and medication management. Additionally, students have access to milieu therapy onsite to support students during the school day. The unique support of milieu, or “therapy on demand,” is to help students cope in vivo by coaching them through crises using effective skills in the moment.

Alexa believes the intimacy of the space itself was helpful for connecting with people. “It’s very easy to socialize because it’s just one floor, in one building. It really helped my social anxiety,” she said. She also used this time to explore several aspects of her cultural and sexual identities. “It wasn’t really a big deal, people weren’t shocked. But it did help me feel more comfortable with who I am.”

Of course, COVID-19 presented problems in providing intensive care. Although CARES offered a blended learning option in the fall of 2020, Alexa attended CARES remotely from March 2020 to March 2021 because of concerns around the pandemic. “It was pretty hard because it made it easier to not go to class and group therapy sessions,” Alexa said. But she persevered with the help of her support network and CARES team.

“Alexa’s capability for deep insight and ability to share is so impressive and constantly inspiring me,” said Dr. Rojas. “Even in the substance group for teens, Alexa told her story and it was so helpful for destigmatizing substance use for the others in the group. To be able to ask for what she needs even when she doesn’t feel like it—after everything she’s been through—is really amazing.”

Graduation and the path forward

The New York City Department of Education and CARES staff unanimously voted Alexa as valedictorian, along with one other student. “I was so confused,” she said. “I really never thought that I would even be considered for that.”

In her speech, Alexa provided sound advice to her peers: “To everyone that is here or still in school, or struggling with mental health, don’t let it get to a point where you regret your choices. Instead, make the choices that will lead you to have a life that you dream of. Whatever advantages or opportunities you get in life, take it, because it could be something wonderful.”

Alexa’s love of animals and art led her to create an Etsy shop: Muffin’s Stickers, named for her dog who passed away in January.

“My life revolves around animals. When Muffin passed, I really fell into a deep void. I wanted to die, and I felt completely empty,” she said. “But once I learned how to deal with it, I realized my dog would want me to continue school.”

Art has always been an escape for Alexa, so she began painting pet portraits, which she converted to stickers based on her art as well as custom commissions. In the beginning her customers were mostly friends and family, then informal marketing via TikTok and at CARES helped her attract more customers.

“It really helps to distract me and keep my days busy,” she said. Down the road, she hopes to earn a pet grooming certification so she can open her own pet shop.

As Alexa joined her family, classmates, and care team in Morningside Park for a graduation celebration, she reflected on the last two years of her life. “I came so close to not achieving any of this,” she said. “I could be under the ground or cremated right now. But I’m glad I didn’t succeed in doing that, because the people I met through CARES are the best people ever. The friends I made in the hospital, and the connections I made with adults really helped me a lot and made me feel less alone. I still feel alone and depressed at times, but then I remember everyone I’ve met and imagine how many more people I can meet.”

Alexa will begin outpatient therapy at Mount Sinai in the coming weeks as part of an individualized continuum of care. In her free time, she stays busy with her Etsy shop and is currently applying to trade school to obtain her pet grooming certification.

Mount Sinai’s Department of Psychiatry is one of the largest and most prolific in the world. With our new series, Inside Mount Sinai Psychiatry, we showcase stories from every corner of our Department including our training programs, patient care teams, and scientists. We believe psychiatry and mental health are the building blocks to fulfilling lives and thriving societies; via these stories about our faculty, trainees, and staff, this series shows the myriad ways we work toward that. Whether it’s manning the front desk of an opioid treatment clinic, researching how psychedelics work in the brain, or training future clinician-scientists, our team is relentlessly pursuing the best for those suffering from mental health issues. 

Sharely Fred Torres, MD: Fostering Culturally Sensitive Therapy

Sharely Fred Torres, MD, with her grandfather in Puerto Rico.

The racial and ethnic disparity in mental health care is a critical issue facing psychiatry—and health care as a whole. Lack of access, a dearth of racially and ethnically diverse providers, and increased need across the board due to ripple effects from COVID-19 have intensified the need for minority providers. The Substance Abuse and Mental Health Services Administration (SAMHSA) launched the APA SAMHSA Minority Fellowship Program to address this. Sharely Fred Torres, MD, a rising second-year resident at The Mount Sinai Hospital, was just awarded this year-long fellowship, which begins in October 2021.

“One reason I knew I wanted to go into psychiatry is that there are so few minority providers, which is not a problem that is unique to psychiatry,” she said. The Mount Sinai Hospital is at the border of two socioeconomically distinct neighborhoods of East Harlem and the Upper East Side, so the inpatient psychiatry unit sees very diverse patient populations. “In my medical training at Mount Sinai, I would say that more than 50 percent of my encounters are in Spanish. I feel really lucky that I can talk to many of my patients in their native language as a bilingual person. They’re much more comfortable with a doctor they can relate to, and more likely to be honest about topics they would otherwise keep hidden.”

The path to psychiatry

Dr. Fred Torres was born and raised in Puerto Rico, and has been interested in pursuing a career in psychiatry since she was young. 

“I realized that working in medicine could allow me to work with all kinds of populations and help people in the most fundamental way possible, which is their health,” she said. Regarding her interest in psychology, she said, “I really liked thinking about what drives people’s behaviors and decisions. It applied to so many interactions I’d had.” Dr. Fred Torres’s psychology course at Harvard was taught by Professor Dan Gilbert, who inspired her to pursue psychology as her college major with an emphasis on social and cognitive neuroscience. She joined Harvard Medical School’s Family Van program, which provided disadvantaged neighborhoods in Boston with preventative health screenings such as blood pressure, cholesterol, and blood sugar levels, as well as medications.

“I loved the medical aspects, like learning how to take someone’s blood pressure, but I also loved listening to their stories,” she said. “When the patients spoke about loss and trauma, it really became clear that the lack of access to mental health services was a huge problem in this community.” It was during these years that she also realized that many of her college peers were navigating emotional stressors in school. “I noticed mental health issues affect everyone. But not everyone seeks care.” This led her to join Harvard’s Student Mental Health Liaisons program to advocate for mental health services for college students. She worked with the director of Harvard University Health Services to ensure that freshman orientation at Harvard featured workshops on mental health services so that freshmen had the information early on, rather than waiting for a crisis to seek help.

In medical school, she became one of the first students at the Icahn School of Medicine at Mount Sinai to be accepted to the Primary Care Scholars Program launched in 2015. Through this four-year scholarship for students interested in providing primary care to underserved communities, she provided longitudinal care for patients in a variety of primary care settings. Her medical school tenure was five years, because she took a scholarly year to research under the mentorship of Adriana Feder, MD, and Mercedes Perez-Rodriguez, MD, PhD. “That year really grounded my interest in psychiatry,” she said.

Research and APA SAMHSA Minority Fellowship Program

Dr. Fred Torres is grateful that she is able to take advantage of the APA SAMHSA Minority Fellowship Program for psychiatry residents who are committed to addressing mental health disparities through a scholarly project. She plans to research cultural components that shape post-trauma trajectories within the World Trade Center (WTC) first-responder cohort that Dr. Feder has been studying for many years as the associate director for research at the WTC Mental Health Program.

“When Hurricane Maria hit Puerto Rico in 2017, I was in the beginning of my scholarly research year. Being directly impacted by that experience made me realize I wanted to shift my learning to focus on trauma-based research,” she said. “I saw how in the face of trauma, despite much loss and hardship, there was also a sense of support growing in the community in Puerto Rico with people at home coming together to support one another through this shared experience. I was proud and inspired by my community.” Dr. Feder let her know that she could learn about trauma by working with the WTC cohort, a unique population affected by the same traumatic event, in which there is a significant Hispanic population as well.

Dr. Fred Torres wants to explore culturally unique resilience factors within this group. “In much of the Hispanic community, no one talks about anxiety or depression,” she said. “Instead, there is a tendency to go to church and pray when faced with life stressors.” She hypothesizes that depending on the individual, the religious factor and other culturally specific variables can serve both as a barrier to and enhancement of resilience, strength, and meaning after a traumatic incident.

Via qualitative individual interviews during her fellowship, she plans to compare the Hispanic WTC cohort to other minority and non-minority counterparts to identify culturally specific factors that contribute (or detract) to resilience. She hopes the findings from her fellowship research are ultimately incorporated into culturally sensitive therapy for trauma. The Mount Sinai Hospital’s psychiatry residency allows time for research projects in the second year, and Dr. Fred Torres’s mentors, Dr. Feder and Dr. Perez-Rodriguez, will guide her in her scholastic work.

Career plans

Once she finishes residency, Dr. Fred Torres hopes to focus on outpatient therapy for many psychiatric conditions such as personality disorders, depression, anxiety, and trauma. “I like the idea of longitudinal, years-long relationships with patients,” she said.

After residency, she hopes to continue to pursue research and academic interests in order to better inform the care she provides patients. “In this career, you can help anybody,” she said. “There’s nobody who doesn’t need health care. I feel privileged to be in a position to help someone on such a fundamental level. But within the field of psychiatry, we face unique challenges to providing care. Our practices are not as clear-cut—you can’t draw someone’s blood and with a biomarker determine that they have depression or anxiety, in the same manner that you can measure someone’s cholesterol level for example. We rely on the psychiatric interview. I enjoy this challenge of working with patients through that subjective space together.”

Furthermore, as she did in medical school and her residency with the Admissions Committees, Dr. Fred Torres hopes to continue efforts to ensure the diversity of the medical field by recruiting diverse medical trainees and increasing academic support for students who are underrepresented and/or disadvantaged in medicine.

Mount Sinai’s Department of Psychiatry is one of the largest and most prolific in the world. With our new series, Inside Mount Sinai Psychiatry, we showcase stories from every corner of our Department including our training programs, patient care teams, and scientists. We believe psychiatry and mental health are the building blocks to fulfilling lives and thriving societies; via these stories about our faculty, trainees, and staff, this series shows the myriad ways we work toward that. Whether it’s manning the front desk of an opioid treatment clinic, researching how psychedelics work in the brain, or training future clinician-scientists, our team is relentlessly pursuing the best for those suffering from mental health issues. 

How Can You Tell if Someone You Know May Have PTSD?

Many people think post-traumatic stress disorder (PTSD) is something that occurs mostly in soldiers returning home from war. Not so. In fact, PTSD affects millions of people throughout the United States, and the numbers are no doubt rising due to the pandemic.

In this Q&A, Jonathan DePierro, PhD, Assistant Professor, Psychiatry, and Clinical and Research Director, Center for Stress, Resilience and Personal Growth at the Icahn School of Medicine at Mount Sinai, explains how PTSD develops, what some of the warning signs are, and why having symptoms of PTSD is not a sign of weakness.

 What is PTSD?

PTSD is a mental health condition that can develop after someone goes through a life-threatening event, like a car accident, combat, or a serious illness; or when sudden life-threatening events happen to a loved one. Seeing and hearing about human suffering and death at work over and over, like medics, nurses, and 911 dispatchers do, can also contribute to PTSD.

Jonathan DePierro, PhD

What are the symptoms of PTSD?

 PTSD involves four types of symptoms that happen at the same time.

  • Intrusions – reliving the event with upsetting memories, nightmares, or flashbacks where it truly feels as if the event is happening all over again
  • Avoidance – trying very hard to avoid any reminders of the trauma, including talking about what happened
  • Negative thoughts and emotions – feeling depressed, angry, numb, mistrustful, guilty, or ashamed
  • Hyperarousal – feeling on edge, irritable, having difficulty concentrating, being easily startled, and having poor sleep

These symptoms also need to last for more than a month, be distressing, and/or cause problems for you in your life.  Some people may notice changes in their mood, behavior, or relationships right after a trauma; but for others who develop PTSD, symptoms might not develop for many months.

What causes PTSD?

One of the important things to keep in mind about PTSD is that it is the result of a person being exposed to death, threatened death, actual or threatened serious injury, or actual or threatened sexual violence, in one or more of the following ways:

  • Experiencing it yourself
  • Witnessing the event(s) firsthand
  • Learning it happened to a loved one
  • Indirect exposure to aversive details of the trauma, usually by nature of one’s job

The American Psychiatric Association estimates that about 7 percent of adults in the United States will develop PTSD during their lives. People who do develop PTSD are not “weak.” They have experienced an event that they struggle to understand, and their bodies and brains are “stuck” replaying the event and all the upsetting emotions that come along with it.

How can you recognize the signs of PTSD in someone you know?

People with PTSD struggle to make sense of what happened to them or what they witnessed. They might have upsetting images or memories of the most upsetting parts of the trauma, even though they spend a lot of time trying to avoid anything that might remind them of what happened. The events feel too overwhelming to think or talk about. Spending time with others feels like a lot of work and more stressful, so people with PTSD might withdraw and spent a lot more time alone. Sleep and attention problems are common, because the body is so “on edge” and still reacting as if the trauma is still happening in the present moment.

We also know that people with PTSD tend to see themselves, the future, and other people in their lives through certain “mental filters.” One example is that people with PTSD often blame themselves for things that happened during the trauma, even though that does not make sense. Some of our health care workers experience “moral injury” – blaming themselves all the time for something they did or did not do during the worst of the pandemic.

How is PTSD diagnosed and treated?

If you are concerned that you may be experiencing symptoms of PTSD, speak with your health care provider. They may refer you to a mental health clinician, who can review your symptoms and make a treatment plan.  You should also know that depression and PTSD often co-occur, so mention any symptoms of depression you may be experiencing to your providers so they can better understand your needs. If you are concerned about a friend or loved one, speak to them and encourage them to seek help.

Treatment for PTSD directly address avoidance, fear, and negative thoughts. Catching  negative thoughts and trying to change them, to make them more realistic and helpful, is a key part of many treatments.  Treatment also involves rebuilding a sense of safety that often feels so absent in people with PTSD. Some people with PTSD also find antidepressant medications to be helpful.